Our results using a large number of prostate cancer specimens are consistent with the notion of KLK2 as a therapeutic target in prostate cancer, with high levels of KLK2 expression maintained across the prostate disease spectrum from LPC to mCRPC. This evidence concerns the gene KLK2 and prostate carcinoma.